Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Multicenter Study Evaluating the Safety and the Efficacy of KTE-X19 in Adult Japanese Subjects With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

NCT06253663 is registered in ClinicalTrials.gov with Kite, A Gilead Company as lead sponsor.

NCT NCT06253663
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06253663 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Multicenter Study Evaluating the Safety and the Efficacy of KTE-X19 in Adult Japanese Subjects With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Lead sponsor
Kite, A Gilead Company
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 18, 2024
Completion date
July 31, 2027
Enrollment
25 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory b-precursor acute lymphoblastic leukemia, relapsed/refractory mantle cell lymphoma